Aethlon Medical (AEMD) Q4 FY26 earnings call

This fiscal year-end call was a clinical and balance-sheet update from a pre-revenue device developer, delivered as prepared remarks plus a short Q&A. The story is one of disciplined survival: management cut spending ~22% while pushing the Hemopurifier oncology trial into its final cohort and clearing a clean DSMB safety review, and it broadened the platform thesis via preclinical extracellular-vesicle work in rheumatoid arthritis and chronic kidney disease. The forward stance is catalyst-driven rather than commercial. Value hinges on completing Cohort 3, the end-of-trial statistical analysis